ReviewCancer communications (London, England)2019
New frontiers in proton therapy: applications in cancers.
Review in Cancer communications (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Tracing scientific progress: thematic shifts and emerging directions in proton therapy for glioma based on top-cited papers.Frontiers in neurologyPooled it
- Six-month evaluation of normal mouse brain side effects: Comparing FLASH and conventional proton partial brain irradiation.Clinical and translational radiation oncology · 2026Article
- Evaluation of a Boron-Conjugated SRC Inhibitor Combined with Proton and X-Ray Irradiation in U-87 MG and U-87 MG IDH1Pharmaceuticals (Basel, Switzerland) · 2026Article
- A Review of 3D-Printed Medical Devices for Cancer Radiation Therapy.Bioengineering (Basel, Switzerland) · 2026Review
- Advances in proton therapy technology and global clinical applications.Frontiers in oncology · 2026Review
- Review
- Assessment of Carrier-Free Metallacarboranes for Targeted Radiation Therapies PBFT and BNCT: Comparative Cellular Effects and Dosimetry Studies with [Pharmaceuticals (Basel, Switzerland) · 2025Article
- Photon and particle radiotherapy induce redundant modular chemotaxis of human lymphocytes.JCI insight · 2025Article
- Application of 3D-printed compensators for proton pencil beam scanning of shallowly localized pediatric tumors.Radiation oncology (London, England) · 2025Article
- Distinct immune responses to proton and photon radiotherapy: implications for anti-PD-L1 combination therapy in colorectal cancer.Journal of translational medicine · 2025Article
- Physiopathological effects of entrance versus distal spread-out Bragg peak on mouse spinal cord neurons.Scientific reports · 2025Article
- Proton beam therapy induces protective immunity via HMGB1-dependent signaling.Frontiers in public health · 2025Article
- A Financial Benefit-Cost Analysis of Advancing Jordan's Medical Tourism: The Case of Proton Therapy.Cureus · 2025Article
- Superior antitumor immune response achieved with proton over photon immunoradiotherapy is amplified by the nanoradioenhancer NBTXR3.Journal of nanobiotechnology · 2024Article
- Beyond success: unveiling the hidden potential of radiotherapy and immunotherapy in solid tumors.Cancer communications (London, England) · 2024Review
- Review
- Precision radiotherapy for nasopharyngeal carcinoma.Precision radiation oncology · 2024Review
- Differences in Patterns of Care and Referral Between Proton and Photon Therapy.International journal of particle therapy · 2024Article
- Commissioning of a novel gantry-less proton therapy system.Frontiers in oncology · 2024Article
- The Anti-Cancer Activity of the Naturally Occurring Dipeptide Carnosine: Potential for Breast Cancer.Cells · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Proton therapy offers dominant advantages over photon therapy due to the unique depth-dose characteristics of proton, which can cause a dramatic reduction in normal tissue doses both distal and proximal to the tumor target volume. In turn, this feature may allow dose escalation to the tumor target volume while sparing the tumor-neighboring susceptible organs at risk, which has the potential to reduce treatment toxicity and improve local control rate, quality of life and survival. Some dosimetric studies in various cancers have demonstrated the advantages over photon therapy in dose distributions. Further, it has been observed that proton therapy confers to substantial clinical advantage over photon therapy in head and neck, breast, hepatocellular, and non-small cell lung cancers. As such, proton therapy is regarded as the standard modality of radiotherapy in many pediatric cancers from the technical point of view. However, due to the limited clinical evidence, there have been concerns about the high cost of proton therapy from an economic point of view. Considering the treatment expenses for late radiation-induced toxicities, cost-effective analysis in many studies have shown that proton therapy is the most cost-effective option for brain, head and neck and selected breast cancers. Additional studies are warranted to better unveil the cost-effective values of proton therapy and to develop newer ways for better protection of normal tissues. This review aims at reviewing the recent studies on proton therapy to explore its benefits and cost-effectiveness in cancers. We strongly believe that proton therapy will be a common radiotherapy modality for most types of solid cancers in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.